Detalhe da pesquisa
1.
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
J Eur Acad Dermatol Venereol
; 37(1): 93-103, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36156312
2.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Dermatol Ther
; 35(8): e15608, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638250
3.
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Dermatol Ther (Heidelb)
; 14(6): 1649-1657, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748344
4.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Clin Med
; 13(2)2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38256629
5.
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
J Dermatolog Treat
; 35(1): 2350760, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714323
6.
Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
Clin Cosmet Investig Dermatol
; 16: 2971-2983, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37881205
7.
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Front Immunol
; 14: 1341708, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38274801
8.
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Front Med (Lausanne)
; 10: 1196966, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37469659
9.
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy.
Patient Prefer Adherence
; 15: 2551-2562, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34824526